We’re proud to be a leader in the treatment of B-cell malignancies. And currently, we’re seeking to do even more. By broadening our scientific discovery efforts across new technologies, we are pursuing our goal of developing cell therapies that are not only more effective and safer, but also able to treat a broader range of cancers.
As we continue to move forward in addressing hematological malignancies, we are developing multiple ways to broaden the use of cell therapy to treat diseases like diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies and hematologic malignancies, including mantle cell lymphoma (MCL), adult and pediatric acute lymphoblastic leukemia (ALL), follicular and marginal zone lymphoma, chronic lymphocytic leukemia (CLL) and indolent Non-Hodgkin Lymphoma.
At Kite, we are always working to expand the potential of our cell therapy work. That's why we've partnered with leading organizations to further our research and development of TCR constructs to identify targets inside the cancer cells of solid tumors, such as human papillomavirus (HPV)-associated cancers so that we can start to treat certain types of solid tumors in the near future.
Current CAR T products are autologous, requiring customized, on-demand manufacturing of each patient’s individualized product, which can result in 2- to 3-week turnaround times, high costs and capacity constraints. To overcome these challenges, Kite is developing “off-the-shelf” allogeneic CAR T cell products using gene editing technology. The allogeneic approach simplifies manufacturing logistics to enable patients to receive treatment faster, decreasing the likelihood of disease progression, and expanding access so more patients can receive lifesaving therapy.